Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Insulin Like Growth Factor II – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.…
PARIS–(BUSINESS WIRE)–Kersia, the global leader in food safety, announces the acquisition of Choisy Laboratories (“Choisy”), a leading developer and manufacturer…
DUBLIN–(BUSINESS WIRE)–The “Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member…
DUBLIN–(BUSINESS WIRE)–The “Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Spinal…
DUBLIN–(BUSINESS WIRE)–The “Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or…
DUBLIN–(BUSINESS WIRE)–The “Diabetic Nephropathy – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Diabetic Nephropathy –…
DUBLIN–(BUSINESS WIRE)–The “Traumatic Brain Injury – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Traumatic Brain…
DUBLIN–(BUSINESS WIRE)–The “Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Non-Alcoholic Steatohepatitis…
DUBLIN–(BUSINESS WIRE)–The “Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s…
Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, today announced a global license agreement for Inflection’s first-in-class PIM/PI3K/mTOR inhibitors.